RecruitingNot Applicable

Graftless TSFE Via Self-tapping Implants

Yemen20 participantsStarted 2024-09-09

Plain-language summary

This prospective clinical trial aims to evaluate the efficiency, safety, and reliability of a minimally invasive graftless transcrestal sinus lifting approach with simultaneous dental implant placement in patients with edentulous posterior maxilla and limited residual bone height. The study investigates bone formation beneath the Schneiderian membrane, implant stability, osseointegration, and long-term implant survival.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adults aged 18-80 years.
✓. Patients with edentulous posterior maxilla.
✓. Residual bone height approximately 4-6 mm.
✓. Indicated for transcrestal sinus membrane elevation.
✓. Good general health (ASA I or II).
✓. Ability to provide written informed consent.
✓. Willingness to attend follow-up visits.

Exclusion criteria

✕. Severe systemic diseases (ASA III or above).
✕. Uncontrolled diabetes mellitus.
✕. Active sinus pathology.
✕. History of radiotherapy in the head and neck region.
✕. Heavy smokers (\>10 cigarettes/day).
✕. Pregnancy or lactation.
✕. Untreated periodontal disease.

What they're measuring

Amount of Newly Formed Bone After Graftless Transcrestal Sinus Elevation

Timeframe: 6 months after surgery

Trial details

NCT IDNCT07424742

SponsorSana'a University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-03-03

View on ClinicalTrials.gov More Edentulous Posterior Maxilla trials